We hope today is manageable and productive. Best of luck, and keep in touch. … GSK plans to depart the biotechnology industry ...

The new branding also precedes GSK’s proposed demerger this year, which will mean it focuses entirely on biopharma innovation ... The GSK name and elements of the incumbent orange logo have been ...

The British pharma’s experience during the third quarter mirrored that of rival Pfizer, which also reported lower sales of ...

GSK PLC said Wednesday that it has agreed to pay $185 million up front and up to $1.525 billion in success-based milestone payments to license an antibody-drug conjugate from Chinese biopharma ...

Quarterly sales of GSK's RSV vaccine dropped more than 70%, following narrower recommendations for who should get the shot.

Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...

GSK has announced a new collaboration with local ... the study of lung diseases and enhance drug development efforts. Be Biopharma raises capital, hits the clinic Be Biopharma Inc. announced ...

British drugmaker GlaxoSmithKline sued Moderna in U.S. federal court in Delaware on Tuesday, accusing it of violating GSK patent rights in messenger RNA technology with its blockbuster COVID-19 ...

Bearish flow noted in GSK (GSK) Pharma with 2,296 puts trading, or 1.2x expected. Most active are May-25 30 puts and Dec-24 38 calls, with total volume in those strikes near 2,500 contracts.

subscribe to our free daily BioPharma Dive newsletter. Recommended Reading RSV vaccine makers remain optimistic about market despite CDC guidance Vaccine maker GSK unveiled new data Tuesday ...

GSK has agreed to acquire the asthma drug specialist Aiolos Bio for a deal worth up to $1.4bn, as it aims to strengthen its respiratory and inflammatory asset pipeline. GSK will pay $1bn upfront ...

To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Sales of GSK’s top-selling vaccines fell sharply during the third quarter amid lower demand ...